CoChat

Rosiglitazone prevents nutritional fibrosis and steatohepatitis in mice

Nan, Yue-Min, Fu, Na, Wu, Wen-Juan, Liang, Bao-Li, Wang, Rong-Qi, Zhao, Su-Xian, Zhao, Jing-Min, Yu, Jun · 2009 · Scandinavian Journal of Gastroenterology
Cited by 75

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Yue-Min Nana*, Na Fua, Wen-Juan Wua, Bao-Li Lianga, Rong-Qi Wanga, Su-Xian Zhaoa, Jing-Min Zhaob & Jun Yucda Department of Traditional and Western Medical Hepatology, the Third Hospital of Hebei Medical University, Shijiazhuang, Chinab Department of Pathology, Beijing 302 Hospital, Beijing, Chinac Institute of Digestive Disease and Li Ka Shing Institute of Health Sciences, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kongd Department of Gastroenterology, the First Hospital of Hebei Medical University, Shijiazhuang, China† Correspondence: Yue-Min Nan, Traditional and Western Medical, Department of Hepatology, Third Hospital of Hebei Medical University, Shijiazhuang, China, +86 311 88602151, +86 311 87023626 nanyuemin@163.comObjective. Currently, no agent has been confirmed as preventing the fibrosing progression of non-alcoholic steatohepatitis (NASH). In this study, rosiglitazone was used in the clinical treatment of insulin resistance in patients with type 2 diabetes mellitus. However, its protective effect on non-alchoholic fibrosing steatohepatitis is not clear. The study aimed to elucidate the effect and the mechanism of rosiglitazone in inhibiting nutrition-related fibrosis in mice. Methods. C57BL6/J mice were fed a high fat, methionine-choline deficient (MCD) diet for 8 weeks to induce hepatic fibrosis, and rosiglitazone was given in the treated group. The effect of rosiglitazone was assessed by comparing the severity of hepatic fibrosis in liver sections, the activation of hepatic stellate cells (HSCs) and the expression of TGF-β1 and connective tissue growth factor (CTGF). Results. At week 8, MCD-diet-induced fibrosing NASH models showed increased serum ALT and AST levels, severe hepatic steatosis, and infiltration of inflammation and fibrosis which, associated with down-regulated PPARγ mRNA and protein expression, up-regulated α-SMA protein expression and enhanced TGF-β1, CTGF mRNA and protein expression. Rosiglitazone significantly lowered serum ALT and AST and it reduced MCD-induced fibrosis by repressing levels of α-SMA protein expression and pro-fibrosis factors TGF-β1 and CTGF. It also restored expression of PPARγ. Conclusions. The present study provides clear morphological and molecular biological evidence of the protective role of rosiglitazone in ameliorating nutritional fibrosing steatohepatitis. Rosiglitazone may ameliorate hepatic fibrosis by activating PPARγ, which can inhibit HSC activation and suppress TGF-β1 and CTGF expression.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/00365520802530861

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 75

Metadata

Authors
Nan, Y.-M., Fu, N., Wu, W.-J., Liang, B.-L., Wang, R.-Q., Zhao, S.-X., Zhao, J.-M., & Yu, J.
Venue
Scandinavian Journal of Gastroenterology
Published
2009-01
Volume
44
Issue
3
Pages
358-365
ISSN
  • 0036-5521 (ISSN-L)
  • 1502-7708
OpenAlex
W2020195767
Cited by
75
References
7
FWCI
3.07
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Rosiglitazone prevents nutritional fibrosis and steatohepatitis in mice. https://app.cochat.ai/papers/10.1080/00365520802530861
The paper
Nan, Y.-M., Fu, N., Wu, W.-J., Liang, B.-L., Wang, R.-Q., Zhao, S.-X., Zhao, J.-M., & Yu, J. (2009). Rosiglitazone prevents nutritional fibrosis and steatohepatitis in mice. Scandinavian Journal of Gastroenterology. https://doi.org/10.1080/00365520802530861

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.